

Biosyngen partners with Singapore's A*STAR to advance autoimmune therapy

03 August 2024 | News

Exploring novel multi-specific antibody therapies targeting plasma cells, ultimately improving patient outcomes



Singapore-based startup Biosyngen has announced a strategic collaboration with Singapore's Agency for Science, Technology and Research (A*STAR) to enhance autoimmune therapy.

The collaborative project involves three of Singapore's preeminent research institutions – Singapore Immunology Network (SIgN), the Institute of Molecular and Cell Biology (IMCB), and the Bioprocessing Technology Institute (BTI) - all operating under the auspices of A*STAR, alongside Biosyngen.

The multi-institute research team, led by Professor Kong Peng Lam, the Executive Director of the SIgN, will work to address the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The project aims to develop a new generation of highly effective and safe multi-specific antibodies to address the treatment of autoimmune diseases and drive significant progress in the self-immune drug market.

Leveraging on Biosyngen's dual R&D and GMP facilities in Guangzhou and Singapore, the outcome of the collaboration will develop a new therapy and commercialise globally; in partnership with the Translational Medicine Center, TMC. It will oversee the project's implementation in the CSGKC, injecting new momentum into biomedicine development in the Greater Bay Area. This collaboration represents the deepening of scientific and technological partnership between China and Singapore.